Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma

Journal of Neuro-Oncology

Volumn 102, Issue 1, 2011, Pages 25-33

  Zitterbart, Karel ^a   Filkova, Hana ^a,b   Tomasikova, Lenka ^a   Necesalova, Eva ^a,b   Zambo, Iva ^c   Kantorova, Dagmar ^a   Slamova, Iva ^a,b   Vranova, Vladimira ^a,b   Zezulkova, Dita ^a,b   Pesakova, Martina ^a,b   Pavelka, Zdenek ^a   Veselska, Renata ^a,b   Kuglik, Petr ^a,b   Sterba, Jaroslav ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Amplification; Gain; I FISH; Medulloblastoma; MYCC; MYCN

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; LOMUSTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENETIC GAIN; HUMAN; HUMAN TISSUE; HYPERPLOIDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; ONCOGENE MYC; ONCOGENE MYCC; ONCOGENE MYCN; OVERALL SURVIVAL; PLOIDY; PROGNOSIS; SCHOOL CHILD; SURVIVAL;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MEDULLOBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79952184632     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0289-3     Document Type: Article

References (51)

1. Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: new biological advances. Lancet Neurol 6:1073-1085. doi:10.1016/S1474-4422(07) 70289-2 (Pubitemid 350116703)
2. Packer RJ, Vezina G (2008) Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 65:1419-1424
3. Pizer BL, Clifford SC (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 23:364-375. doi:10.1080/02688690903121807
4. Johnsen JI, Kogner P, Albihn A, Henriksson MA (2009) Embryonal neural tumours and cell death. Apoptosis 14:424-438. doi:10.1007/s10495-009-0325-y
5. Curran EK, Le GM, Sainani KL, Propp JM, Fisher PG (2009) Do children and adults differ in survival from medulloblastoma? A study from the SEER registry. J Neurooncol 95:81-85. doi: 10.1007/s11060-009-9894-4
6. Frange P, Alapetite C, Gaboriaud G, Bours D, Zucker JM, Zerah M, Brisse H, Chevignard M, Mosseri V, Bouffet E, Doz F (2009) From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000). J Neurooncol 95:271-279. doi:10.1007/s11060-009-9927-z
7. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202-4208. doi:10.1200/JCO.2006.06.4980
8. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy followed by highdose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): longterm results from a prospective, multicentre trial. Lancet Oncol 7:813-820. doi:10.1016/S1470- 2045(06)70867-1 (Pubitemid 44464063)
9. Valteau-Couanet D, Fillipini B, Benhamou E, Grill J, Kalifa C, Couanet D, Habrand JL, Hartmann O (2005) High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 36:939-945. doi:10.1038/sj.bmt.1705162 (Pubitemid 41741555)
10. Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastri D, Ravagnani F, Fossati-Bellani F (2009) No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys 73:1358-1363. doi:10.1016/j.ijrobp.2008.06.1930
11. Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S (2010) A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol 97:247-255. doi:10.1007/s11060-009-0009-z
12. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD, Kuehl J (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978-986 (Pubitemid 40349500)
13. McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor RE, Grundy RG, Clifford SC, Ellison DW (2007) Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17:151-164. doi:10.1111/j.1750-3639.2007.00058.x (Pubitemid 46466135)
14. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, Kun LE, Goldthwaite PT, Burger PC (2000) "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865
15. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, DuVner PK, Friedman HS, Strother DR, Burger PC (2002) Histopathologic grading of medulloblastomas: a pediatric oncology group study. Cancer 94:552-560. doi:10.1002/cncr.10189 (Pubitemid 34081387)
16. McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, Ellison DW (2003) Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62:627-632
17. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493. doi:10.1158/1078-0432. CCR-03-0721 (Pubitemid 39100486)
18. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636. doi:10.1200/JCO.2008.17.9432
19. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sörensen N, Kühl J (1998) Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485 (Pubitemid 28309044)
20. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126:540-544
21. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103-3111 (Pubitemid 38581410)
22. Takei H, Nguyen Y, Mehta V, Chintagumpala M, Dauser RC, Adesina AM (2009) Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. J Neurosurg Pediatr 3:61-65. doi:10.3171/2008.10.PEDS08105
23. Herms J, Neidt I, Lüscher B, Sommer A, Schürmann P, Schröder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA (2000) C-myc expression in medulloblastoma and its prognsotic value. Int J Cancer 89:395-402. doi:10.1002/1097-0215(20000920)89:5\395:AID-IJC1[3.0.CO;2-V
24. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN, Rorke LB, Brodeur GM, Phillips PC (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433 (Pubitemid 32751645)
25. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC (2004) Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449 (Pubitemid 38669665)
26. Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, Zhao H, Cnaan A, Phillips PC, Lee VM, Trojanowski JQ (2000) TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18:1027-1035 (Pubitemid 30123779)
27. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13:2651-2657. doi:10.1158/1078-0432.CCR-06-1779 (Pubitemid 46788032)
28. Pizem J, Cört A, Zadravec-Zaletel L, Popovic M (2005) Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31:422-428. doi:10.1111/j.1365-2990.2005.00664.x (Pubitemid 41059863)
29. Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G, Schindler C, Jones N, Klein-Franke A, Maier H, Jauk B, Kiefer A, Hainfellner JA (2006) Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 42:2996-3003. doi:10.1016/j.ejca.2006.05.038 (Pubitemid 44755258)
30. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC (2005) beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957. doi:10.1200/JCO.2005.01.5479
31. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW (2006) Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666-2670
32. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218:86-94. doi: 10.1002/path.2514
33. Ruggero D (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69:8839-8843. doi:10.1158/0008-5472.CAN-09-1970
34. Necesalova E, Vranova V, Kuglik P, Cejpek P, Jarosova M, Pesakova M, Relichova J, Veselska R (2007) Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology. Neoplasma 54:212-218
35. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He XM, Wikstrand CJ, Kurtzberg J, Berens ME, Halperin EC, Bigner DD (1988) Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 130:472-484 (Pubitemid 18091375)
36. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Galassi E, Giangaspero F (1991) N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 77:118-121
37. Rasheed BK, Bigner SH (1991) Genetic alterations in glioma and medulloblastoma. Cancer Metastasis Rev 10:289-299. doi: 10.1007/BF00554791
38. Tomlinson FH, Jenkins RB, Scheithauer BW, Keelan PA, Ritland S, Parisi JE, Cunningham J, Olsen KD (1994) Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clin Proc 69:359-365 (Pubitemid 24108186)
39. Bruggers CS, Tai KF, Murdock T, Sivak L, Le K, Perkins SL, Coffin CM, Carroll WL (1998) Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 20: 18-25 (Pubitemid 28119751)
40. Jay V, Squire J, Bayani J, Alkhani AM, Rutka JT, Zielenska M (1999) Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology 31:337-344 (Pubitemid 30009093)
41. Kucerova H, Stejskalova E, Vicha A, Tichy M, Chanova M, Sumerauer D, Koutecky J, Eckschlager T (2000) Gene aberrations in childhood brain tumors. Folia Biol (Praha) 46:187-190
42. Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB (2000) Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg 102:203-209. doi:10.1016/S0303-8467(00)00112-8 (Pubitemid 32012615)
43. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC (2002) Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12:36-44. doi:10.1111/j.1750-3639.2002.tb00420.x (Pubitemid 33131360)
44. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG (2006) c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 66:673-681. doi:10.1158/0008-5472.CAN-05-1580 (Pubitemid 43165929)
45. Garson JA, Pemberton LF, Sheppard PW, Varndell IM, Coakham HB, Kemshead JT (1989) N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br J Cancer 59:889-894 (Pubitemid 19155702)
46. Malakho SG, Korshunov A, Stroganova AM, Poltaraus AB (2008) Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR. J Clin Lab Anal 22:123-130. doi:10.1002/jcla.20232 (Pubitemid 351543944)
47. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471-1482. doi:10.1038/sj.bjc.6605014
48. Souzaki R, Tajiri T, Higashi M, Kinoshita Y, Tanaka S, Kohashi K, Tsuneyoshi M, Taguchi T (2008) Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR. Pediatr Surg Int 24:1095-1100. doi:10.1007/s00383-008-2228-3
49. Ryott M, Wangsa D, Heselmeyer-Haddad K, Lindholm J, Elmberger G, Auer G, Avall Lundqvist E, Ried T, Munck-Wikland E (2009) EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur J Cancer 45:1700-1708. doi:10.1016/j.ejca.2009.02.027
50. Zerbini C, Gelber RD, Weinberg D, Sallan SE, Barnes P, Kupsky W, Scott RM, Tarbell NJ (1993) Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 11:616-622 (Pubitemid 23105668)
51. Latimer FR, AlSaadi AA, Robbins TO (1987) Cytogenetic studies of human brain tumors and their clinical significance. 1. Medulloblastoma. J Neurooncol 4:287-291. doi:10.1007/BF00150618 (Pubitemid 17023827)